| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 89 | 2023 | 1802 | 9.290 |
Why?
|
| Chordoma | 27 | 2023 | 343 | 5.450 |
Why?
|
| Spinal Neoplasms | 23 | 2022 | 708 | 3.770 |
Why?
|
| Soft Tissue Neoplasms | 30 | 2023 | 1165 | 3.740 |
Why?
|
| Retroperitoneal Neoplasms | 20 | 2021 | 335 | 3.510 |
Why?
|
| Extremities | 25 | 2018 | 869 | 2.610 |
Why?
|
| Sacrum | 13 | 2023 | 270 | 2.170 |
Why?
|
| Radiotherapy Dosage | 52 | 2021 | 2865 | 2.010 |
Why?
|
| Photons | 17 | 2019 | 572 | 1.960 |
Why?
|
| Bone Neoplasms | 22 | 2021 | 2567 | 1.780 |
Why?
|
| Radiation Oncology | 13 | 2021 | 569 | 1.740 |
Why?
|
| Radiotherapy, Conformal | 15 | 2020 | 533 | 1.660 |
Why?
|
| Radiotherapy | 13 | 2021 | 1494 | 1.420 |
Why?
|
| Osteosarcoma | 11 | 2019 | 909 | 1.230 |
Why?
|
| Tumor Burden | 15 | 2017 | 1885 | 1.110 |
Why?
|
| Radiotherapy, Adjuvant | 28 | 2021 | 1776 | 1.100 |
Why?
|
| Neoplasm Recurrence, Local | 39 | 2021 | 9373 | 1.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 19 | 2021 | 1643 | 1.030 |
Why?
|
| Chondrosarcoma | 8 | 2019 | 301 | 0.990 |
Why?
|
| Fibromatosis, Aggressive | 6 | 2019 | 125 | 0.930 |
Why?
|
| Radiotherapy, Intensity-Modulated | 11 | 2020 | 784 | 0.840 |
Why?
|
| Neoadjuvant Therapy | 20 | 2021 | 2895 | 0.830 |
Why?
|
| Cauda Equina | 1 | 2021 | 45 | 0.740 |
Why?
|
| Radiotherapy, High-Energy | 4 | 2018 | 226 | 0.680 |
Why?
|
| Abdominal Neoplasms | 3 | 2017 | 284 | 0.640 |
Why?
|
| Neoplasms, Second Primary | 6 | 2020 | 1050 | 0.640 |
Why?
|
| Spinal Cord Neoplasms | 3 | 2017 | 258 | 0.600 |
Why?
|
| Organs at Risk | 7 | 2020 | 352 | 0.580 |
Why?
|
| Brachytherapy | 9 | 2021 | 1222 | 0.580 |
Why?
|
| Chondrosarcoma, Mesenchymal | 1 | 2016 | 13 | 0.550 |
Why?
|
| Combined Modality Therapy | 44 | 2021 | 8529 | 0.520 |
Why?
|
| Negative-Pressure Wound Therapy | 3 | 2022 | 156 | 0.490 |
Why?
|
| Humans | 225 | 2023 | 765968 | 0.480 |
Why?
|
| Misonidazole | 1 | 2014 | 33 | 0.480 |
Why?
|
| Thoracic Vertebrae | 3 | 2015 | 614 | 0.480 |
Why?
|
| Radiation Injuries | 14 | 2016 | 1181 | 0.470 |
Why?
|
| Lumbar Vertebrae | 5 | 2023 | 1873 | 0.460 |
Why?
|
| Aged | 96 | 2021 | 171117 | 0.450 |
Why?
|
| Preoperative Care | 9 | 2021 | 2267 | 0.440 |
Why?
|
| Spine | 3 | 2017 | 1128 | 0.440 |
Why?
|
| Middle Aged | 111 | 2021 | 223009 | 0.440 |
Why?
|
| Skull Base Neoplasms | 2 | 2016 | 276 | 0.430 |
Why?
|
| Aged, 80 and over | 46 | 2021 | 59489 | 0.430 |
Why?
|
| Disease-Free Survival | 16 | 2018 | 6832 | 0.420 |
Why?
|
| Adult | 103 | 2021 | 223044 | 0.420 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 267 | 0.400 |
Why?
|
| Histiocytoma, Malignant Fibrous | 3 | 2014 | 54 | 0.400 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 647 | 0.390 |
Why?
|
| Photochemotherapy | 11 | 1997 | 826 | 0.390 |
Why?
|
| Neoplasms | 15 | 2020 | 22340 | 0.390 |
Why?
|
| Treatment Outcome | 50 | 2022 | 65188 | 0.380 |
Why?
|
| Patient Positioning | 2 | 2013 | 328 | 0.380 |
Why?
|
| Scattering, Radiation | 3 | 2017 | 482 | 0.370 |
Why?
|
| Medication Reconciliation | 1 | 2013 | 153 | 0.360 |
Why?
|
| Liposarcoma | 4 | 2016 | 288 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2019 | 11868 | 0.350 |
Why?
|
| Retrospective Studies | 50 | 2022 | 81514 | 0.340 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2017 | 3537 | 0.340 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 1998 | 347 | 0.340 |
Why?
|
| Head and Neck Neoplasms | 7 | 2014 | 2921 | 0.330 |
Why?
|
| Follow-Up Studies | 31 | 2019 | 39193 | 0.330 |
Why?
|
| Spinal Cord | 2 | 2016 | 1784 | 0.330 |
Why?
|
| Male | 124 | 2021 | 363698 | 0.320 |
Why?
|
| Adolescent | 45 | 2021 | 88835 | 0.320 |
Why?
|
| Female | 127 | 2021 | 396112 | 0.320 |
Why?
|
| Survival Rate | 26 | 2019 | 12795 | 0.320 |
Why?
|
| Relative Biological Effectiveness | 8 | 2017 | 299 | 0.320 |
Why?
|
| Young Adult | 33 | 2021 | 59889 | 0.320 |
Why?
|
| Medical History Taking | 1 | 2013 | 777 | 0.310 |
Why?
|
| Dose-Response Relationship, Radiation | 9 | 2019 | 869 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2023 | 20659 | 0.300 |
Why?
|
| Cyclotrons | 1 | 2007 | 30 | 0.290 |
Why?
|
| Radiodermatitis | 3 | 2019 | 58 | 0.290 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2019 | 540 | 0.280 |
Why?
|
| Hematoporphyrin Photoradiation | 5 | 1994 | 17 | 0.280 |
Why?
|
| Medical Records | 1 | 2013 | 1409 | 0.280 |
Why?
|
| Protons | 4 | 2022 | 1073 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 7 | 2017 | 7425 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2019 | 6499 | 0.260 |
Why?
|
| Neoplasm, Residual | 5 | 2014 | 1009 | 0.260 |
Why?
|
| Consensus | 8 | 2021 | 3202 | 0.260 |
Why?
|
| Postoperative Care | 5 | 2021 | 1470 | 0.260 |
Why?
|
| Cholangiocarcinoma | 3 | 2018 | 578 | 0.260 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2016 | 243 | 0.260 |
Why?
|
| Isotretinoin | 2 | 1998 | 135 | 0.250 |
Why?
|
| Fractures, Spontaneous | 2 | 2019 | 230 | 0.250 |
Why?
|
| Radiosurgery | 3 | 2020 | 1328 | 0.250 |
Why?
|
| Fibrosarcoma | 2 | 2021 | 313 | 0.250 |
Why?
|
| Retreatment | 2 | 2021 | 598 | 0.250 |
Why?
|
| Dihematoporphyrin Ether | 4 | 1994 | 33 | 0.240 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2699 | 0.240 |
Why?
|
| Physicians | 1 | 2023 | 4588 | 0.230 |
Why?
|
| Nerve Sheath Neoplasms | 2 | 2019 | 170 | 0.230 |
Why?
|
| Anus Neoplasms | 2 | 2019 | 336 | 0.230 |
Why?
|
| Neoplasm Staging | 17 | 2021 | 11206 | 0.230 |
Why?
|
| Liver Neoplasms | 5 | 2019 | 4353 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2019 | 2329 | 0.220 |
Why?
|
| Enteritis | 1 | 2005 | 163 | 0.220 |
Why?
|
| Iridium Radioisotopes | 1 | 2003 | 26 | 0.220 |
Why?
|
| Fluorouracil | 5 | 2019 | 1648 | 0.220 |
Why?
|
| Limb Salvage | 3 | 2016 | 488 | 0.220 |
Why?
|
| Osteotomy | 1 | 2009 | 833 | 0.210 |
Why?
|
| Pancreatic Neoplasms | 7 | 2019 | 5444 | 0.210 |
Why?
|
| Interferon-alpha | 2 | 1998 | 910 | 0.210 |
Why?
|
| Bandages | 2 | 2021 | 269 | 0.210 |
Why?
|
| Feasibility Studies | 11 | 2019 | 5302 | 0.210 |
Why?
|
| Hemangiosarcoma | 2 | 2020 | 211 | 0.210 |
Why?
|
| Particle Accelerators | 2 | 2018 | 174 | 0.200 |
Why?
|
| Prognosis | 23 | 2021 | 29922 | 0.200 |
Why?
|
| Yttrium Radioisotopes | 1 | 2003 | 116 | 0.200 |
Why?
|
| Survival Analysis | 13 | 2019 | 10070 | 0.200 |
Why?
|
| Doxorubicin | 7 | 2012 | 2230 | 0.200 |
Why?
|
| Mesna | 4 | 2012 | 62 | 0.190 |
Why?
|
| Biopsy, Needle | 2 | 2006 | 1628 | 0.190 |
Why?
|
| Ifosfamide | 5 | 2012 | 233 | 0.190 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2015 | 2056 | 0.190 |
Why?
|
| Intraoperative Period | 4 | 2010 | 508 | 0.190 |
Why?
|
| Dura Mater | 1 | 2003 | 296 | 0.190 |
Why?
|
| Positron-Emission Tomography | 3 | 2020 | 6547 | 0.190 |
Why?
|
| Abdominal Wall | 2 | 2014 | 166 | 0.180 |
Why?
|
| Neurofibromatosis 1 | 2 | 2019 | 560 | 0.180 |
Why?
|
| Boronic Acids | 1 | 2005 | 916 | 0.180 |
Why?
|
| Eye Diseases | 1 | 2006 | 659 | 0.180 |
Why?
|
| Proteome | 1 | 2010 | 1899 | 0.180 |
Why?
|
| Child | 27 | 2019 | 80564 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 4034 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2019 | 4044 | 0.170 |
Why?
|
| Nephrectomy | 2 | 2015 | 927 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2017 | 36532 | 0.170 |
Why?
|
| Treatment Failure | 6 | 2017 | 2652 | 0.170 |
Why?
|
| Thoracic Wall | 2 | 2013 | 197 | 0.170 |
Why?
|
| Pyrazines | 1 | 2005 | 1204 | 0.160 |
Why?
|
| Arm | 2 | 2013 | 589 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 2 | 2015 | 626 | 0.160 |
Why?
|
| Disease Management | 2 | 2021 | 2535 | 0.150 |
Why?
|
| Dacarbazine | 4 | 2012 | 552 | 0.150 |
Why?
|
| Breast Neoplasms | 11 | 2020 | 21056 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 3596 | 0.150 |
Why?
|
| Abdominal Fat | 1 | 2020 | 217 | 0.150 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2014 | 616 | 0.150 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2017 | 36 | 0.150 |
Why?
|
| Radiometry | 4 | 2013 | 804 | 0.150 |
Why?
|
| Child, Preschool | 16 | 2019 | 42500 | 0.150 |
Why?
|
| Medulloblastoma | 2 | 2017 | 658 | 0.140 |
Why?
|
| Radiography | 7 | 2015 | 6919 | 0.140 |
Why?
|
| Deoxycytidine | 2 | 2014 | 889 | 0.140 |
Why?
|
| Losartan | 1 | 2019 | 263 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 3 | 1993 | 703 | 0.140 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2018 | 70 | 0.140 |
Why?
|
| Prospective Studies | 18 | 2019 | 54802 | 0.140 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 1995 | 135 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2005 | 916 | 0.140 |
Why?
|
| Proteomics | 1 | 2010 | 3910 | 0.140 |
Why?
|
| Liver Failure | 1 | 2019 | 252 | 0.130 |
Why?
|
| Time Factors | 16 | 2019 | 40065 | 0.130 |
Why?
|
| Radiation Tolerance | 4 | 2015 | 475 | 0.130 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2016 | 44 | 0.130 |
Why?
|
| Postoperative Complications | 8 | 2018 | 15747 | 0.130 |
Why?
|
| Cell Dedifferentiation | 1 | 2016 | 125 | 0.120 |
Why?
|
| Pleural Neoplasms | 4 | 1994 | 581 | 0.120 |
Why?
|
| Ireland | 2 | 2013 | 170 | 0.120 |
Why?
|
| Intestine, Small | 4 | 2017 | 1214 | 0.120 |
Why?
|
| Algorithms | 8 | 2023 | 14071 | 0.120 |
Why?
|
| Sacrococcygeal Region | 1 | 2014 | 52 | 0.120 |
Why?
|
| Th2 Cells | 4 | 2001 | 1075 | 0.120 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 2001 | 894 | 0.110 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 249 | 0.110 |
Why?
|
| Liposarcoma, Myxoid | 2 | 2014 | 60 | 0.110 |
Why?
|
| Pyrimidines | 3 | 2018 | 3047 | 0.110 |
Why?
|
| Nose Neoplasms | 1 | 2016 | 249 | 0.110 |
Why?
|
| Pain, Intractable | 1 | 1994 | 132 | 0.110 |
Why?
|
| Linear Energy Transfer | 3 | 2017 | 147 | 0.110 |
Why?
|
| Skin Neoplasms | 4 | 2007 | 5849 | 0.110 |
Why?
|
| Pelvic Neoplasms | 1 | 2015 | 247 | 0.110 |
Why?
|
| Perfusion Imaging | 1 | 2015 | 193 | 0.110 |
Why?
|
| Databases, Factual | 4 | 2017 | 8067 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2009 | 6203 | 0.100 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2013 | 52 | 0.100 |
Why?
|
| Fibromatosis, Abdominal | 1 | 2012 | 21 | 0.100 |
Why?
|
| Myxosarcoma | 1 | 2012 | 11 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 587 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 368 | 0.100 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 12509 | 0.100 |
Why?
|
| Mastocytosis | 1 | 1994 | 151 | 0.100 |
Why?
|
| Cerebellar Neoplasms | 1 | 2017 | 571 | 0.100 |
Why?
|
| Observer Variation | 3 | 2015 | 2615 | 0.100 |
Why?
|
| Sarcoma, Synovial | 2 | 2014 | 155 | 0.100 |
Why?
|
| Preoperative Period | 2 | 2012 | 566 | 0.100 |
Why?
|
| Hepatectomy | 1 | 2015 | 589 | 0.090 |
Why?
|
| Endpoint Determination | 1 | 2014 | 591 | 0.090 |
Why?
|
| Antineoplastic Agents | 8 | 2015 | 13648 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 618 | 0.090 |
Why?
|
| Professional Staff Committees | 2 | 2001 | 37 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2014 | 1758 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 679 | 0.090 |
Why?
|
| Bone Diseases | 1 | 1994 | 411 | 0.090 |
Why?
|
| Bone Density | 1 | 2023 | 3491 | 0.090 |
Why?
|
| Lung Neoplasms | 6 | 2020 | 13451 | 0.090 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 586 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 1119 | 0.090 |
Why?
|
| Medical Illustration | 1 | 2011 | 134 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 647 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 723 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2023 | 8733 | 0.090 |
Why?
|
| Foot | 1 | 1994 | 573 | 0.090 |
Why?
|
| Terminology as Topic | 2 | 2014 | 1534 | 0.080 |
Why?
|
| Radiation Dosage | 5 | 2017 | 1944 | 0.080 |
Why?
|
| Thigh | 1 | 2011 | 238 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 1661 | 0.080 |
Why?
|
| Intraoperative Care | 5 | 2017 | 760 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2017 | 1055 | 0.080 |
Why?
|
| Biopsy | 1 | 2021 | 6763 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10429 | 0.080 |
Why?
|
| Edema | 1 | 2013 | 760 | 0.080 |
Why?
|
| Immunoconjugates | 3 | 2001 | 981 | 0.080 |
Why?
|
| Hand | 1 | 1994 | 909 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2015 | 703 | 0.080 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 6364 | 0.080 |
Why?
|
| Photosensitizing Agents | 1 | 1993 | 625 | 0.080 |
Why?
|
| Th1 Cells | 4 | 2001 | 1039 | 0.080 |
Why?
|
| Perception | 1 | 2015 | 1205 | 0.080 |
Why?
|
| Quality of Life | 5 | 2021 | 13462 | 0.080 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2009 | 75 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1560 | 0.080 |
Why?
|
| Brain Neoplasms | 6 | 2014 | 9071 | 0.080 |
Why?
|
| Lower Extremity | 2 | 2013 | 1226 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 1404 | 0.070 |
Why?
|
| beta Catenin | 1 | 2013 | 1043 | 0.070 |
Why?
|
| Mastectomy | 2 | 2013 | 1847 | 0.070 |
Why?
|
| Drug Information Services | 1 | 2008 | 51 | 0.070 |
Why?
|
| Furans | 1 | 2009 | 198 | 0.070 |
Why?
|
| Massachusetts | 3 | 2010 | 8875 | 0.070 |
Why?
|
| Wound Healing | 2 | 2012 | 2792 | 0.070 |
Why?
|
| Mitomycin | 2 | 2019 | 261 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 2074 | 0.070 |
Why?
|
| Chondromatosis, Synovial | 1 | 2007 | 17 | 0.070 |
Why?
|
| Imidazoles | 2 | 2004 | 1162 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 5197 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 1203 | 0.070 |
Why?
|
| Lymphangiosarcoma | 1 | 2006 | 14 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 3529 | 0.070 |
Why?
|
| Respiration | 1 | 2013 | 1653 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2016 | 6322 | 0.070 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 2004 | 89 | 0.070 |
Why?
|
| Lung | 6 | 2006 | 10033 | 0.070 |
Why?
|
| Muscle Neoplasms | 1 | 2008 | 130 | 0.070 |
Why?
|
| Osteolysis, Essential | 1 | 2006 | 30 | 0.070 |
Why?
|
| Facility Design and Construction | 1 | 2007 | 88 | 0.070 |
Why?
|
| Research Design | 3 | 2014 | 6209 | 0.070 |
Why?
|
| Radiation-Protective Agents | 3 | 1992 | 87 | 0.070 |
Why?
|
| Carbon | 1 | 2010 | 677 | 0.060 |
Why?
|
| Microvessels | 1 | 2010 | 591 | 0.060 |
Why?
|
| Vascular Neoplasms | 1 | 2008 | 167 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 5 | 2009 | 6113 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 2887 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2006 | 790 | 0.060 |
Why?
|
| Leiomyosarcoma | 1 | 2010 | 423 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 2942 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2006 | 254 | 0.060 |
Why?
|
| Phototherapy | 2 | 2004 | 370 | 0.060 |
Why?
|
| Patient Admission | 1 | 2013 | 1365 | 0.060 |
Why?
|
| Disease Progression | 6 | 2019 | 13632 | 0.060 |
Why?
|
| Radiation Pneumonitis | 2 | 2018 | 98 | 0.060 |
Why?
|
| Fingers | 1 | 2008 | 509 | 0.060 |
Why?
|
| Glioma | 3 | 1995 | 3493 | 0.060 |
Why?
|
| Risk Factors | 9 | 2020 | 74840 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2009 | 728 | 0.060 |
Why?
|
| Fractures, Bone | 2 | 2013 | 2041 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2013 | 1378 | 0.060 |
Why?
|
| Age Factors | 6 | 2017 | 18380 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2015 | 2517 | 0.060 |
Why?
|
| Skull Neoplasms | 1 | 2005 | 173 | 0.060 |
Why?
|
| Cause of Death | 3 | 2019 | 3708 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 878 | 0.050 |
Why?
|
| Acclimatization | 1 | 1984 | 113 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2019 | 3785 | 0.050 |
Why?
|
| Equipment Design | 2 | 2007 | 3481 | 0.050 |
Why?
|
| Carcinoma | 2 | 2004 | 2312 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 5389 | 0.050 |
Why?
|
| Internal Fixators | 1 | 2004 | 183 | 0.050 |
Why?
|
| North America | 2 | 2018 | 1285 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5526 | 0.050 |
Why?
|
| Ilium | 1 | 2023 | 154 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 1986 | 1029 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 2495 | 0.050 |
Why?
|
| Hemangioma | 1 | 2008 | 723 | 0.050 |
Why?
|
| Idoxuridine | 2 | 1993 | 111 | 0.050 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 10261 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2009 | 1611 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 4752 | 0.050 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2001 | 271 | 0.050 |
Why?
|
| Patient Selection | 2 | 2012 | 4255 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 3646 | 0.050 |
Why?
|
| Pentobarbital | 3 | 1992 | 153 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 4893 | 0.050 |
Why?
|
| SEER Program | 2 | 2017 | 1446 | 0.050 |
Why?
|
| Documentation | 1 | 2008 | 916 | 0.050 |
Why?
|
| Europe | 2 | 2018 | 3423 | 0.050 |
Why?
|
| Hematoma | 1 | 2006 | 766 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2010 | 11083 | 0.050 |
Why?
|
| United States | 7 | 2017 | 72903 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2004 | 426 | 0.050 |
Why?
|
| Clinical Trials as Topic | 5 | 2008 | 8041 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 1133 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 2310 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 1078 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2004 | 436 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2013 | 3956 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2006 | 566 | 0.040 |
Why?
|
| Acute Disease | 2 | 2015 | 7232 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 2453 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 1668 | 0.040 |
Why?
|
| Radiation | 1 | 2020 | 48 | 0.040 |
Why?
|
| Infant | 7 | 2018 | 36386 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 1986 | 1259 | 0.040 |
Why?
|
| Shoulder Joint | 1 | 2007 | 740 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 41649 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 4058 | 0.040 |
Why?
|
| Receptors, Chemokine | 2 | 2001 | 651 | 0.040 |
Why?
|
| Hematoporphyrins | 3 | 1989 | 23 | 0.040 |
Why?
|
| Respiratory Mucosa | 2 | 2001 | 438 | 0.040 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2001 | 300 | 0.040 |
Why?
|
| Interleukin-3 | 1 | 2001 | 423 | 0.040 |
Why?
|
| Immunity, Mucosal | 2 | 2001 | 498 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2017 | 1820 | 0.040 |
Why?
|
| Risk | 4 | 2018 | 9591 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2015 | 4863 | 0.040 |
Why?
|
| Bone Transplantation | 1 | 2004 | 920 | 0.040 |
Why?
|
| Infection Control | 1 | 2006 | 983 | 0.040 |
Why?
|
| Research | 1 | 2007 | 1975 | 0.040 |
Why?
|
| Colostomy | 1 | 2019 | 107 | 0.040 |
Why?
|
| Animals | 18 | 2018 | 168764 | 0.040 |
Why?
|
| Mitotic Index | 2 | 2016 | 159 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2014 | 512 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2000 | 416 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 1662 | 0.040 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1999 | 260 | 0.040 |
Why?
|
| Muscles | 1 | 2023 | 1578 | 0.040 |
Why?
|
| Hematoporphyrin Derivative | 2 | 1988 | 10 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 26318 | 0.040 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
| Palliative Care | 3 | 2007 | 3645 | 0.040 |
Why?
|
| Contrast Media | 1 | 2011 | 5329 | 0.040 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2017 | 58 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 6493 | 0.040 |
Why?
|
| Hemoglobin A | 1 | 1997 | 84 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 2844 | 0.040 |
Why?
|
| Leucovorin | 1 | 2019 | 641 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 6 | 2001 | 6220 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1984 | 1433 | 0.030 |
Why?
|
| Stomach | 2 | 2015 | 699 | 0.030 |
Why?
|
| Pyridines | 1 | 2009 | 2888 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 10383 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2018 | 315 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 305 | 0.030 |
Why?
|
| Ovarian Neoplasms | 2 | 1993 | 4900 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 943 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 2004 | 2229 | 0.030 |
Why?
|
| Anal Canal | 1 | 2019 | 376 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1996 | 116 | 0.030 |
Why?
|
| Orgasm | 1 | 2016 | 63 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 163 | 0.030 |
Why?
|
| Mitochondrial Size | 1 | 2015 | 8 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2016 | 110 | 0.030 |
Why?
|
| Cell Survival | 3 | 2002 | 5747 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2001 | 533 | 0.030 |
Why?
|
| Mutation | 3 | 2017 | 30198 | 0.030 |
Why?
|
| Electrons | 1 | 2017 | 265 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2000 | 728 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2001 | 995 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 2002 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 1996 | 166 | 0.030 |
Why?
|
| Vermont | 1 | 2015 | 80 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 20124 | 0.030 |
Why?
|
| Growth Plate | 1 | 2017 | 273 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 2015 | 133 | 0.030 |
Why?
|
| Survivors | 2 | 2014 | 2372 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2008 | 3461 | 0.030 |
Why?
|
| Spinal Fusion | 1 | 2004 | 1302 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 9525 | 0.030 |
Why?
|
| Surgical Wound Infection | 2 | 2022 | 1543 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 3356 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 14652 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2016 | 393 | 0.030 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1994 | 41 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 12056 | 0.030 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1994 | 44 | 0.030 |
Why?
|
| Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
| Mastectomy, Radical | 1 | 1993 | 19 | 0.030 |
Why?
|
| Models, Biological | 1 | 2010 | 9443 | 0.030 |
Why?
|
| CA-19-9 Antigen | 1 | 2014 | 109 | 0.030 |
Why?
|
| Mastectomy, Simple | 1 | 1993 | 23 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2015 | 251 | 0.030 |
Why?
|
| Cell Division | 2 | 1996 | 4475 | 0.030 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1993 | 59 | 0.030 |
Why?
|
| Antigens, Differentiation | 3 | 2001 | 919 | 0.030 |
Why?
|
| Skull Base | 1 | 2016 | 293 | 0.030 |
Why?
|
| Farnesyltranstransferase | 2 | 2004 | 70 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 1434 | 0.030 |
Why?
|
| Femoral Neoplasms | 1 | 1993 | 85 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 683 | 0.030 |
Why?
|
| Heart | 1 | 2006 | 4414 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2014 | 337 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 5696 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 1996 | 2228 | 0.030 |
Why?
|
| Leukocytes | 1 | 2001 | 2027 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 268 | 0.030 |
Why?
|
| Incidence | 4 | 2019 | 21480 | 0.020 |
Why?
|
| Pleura | 1 | 1994 | 240 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2013 | 307 | 0.020 |
Why?
|
| Giant Cells | 1 | 2012 | 187 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 2207 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2017 | 2910 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2016 | 408 | 0.020 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1992 | 88 | 0.020 |
Why?
|
| Duodenum | 1 | 2015 | 495 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2016 | 1216 | 0.020 |
Why?
|
| Thymidine | 1 | 1992 | 294 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2018 | 4405 | 0.020 |
Why?
|
| Barbiturates | 1 | 1992 | 113 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 891 | 0.020 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 491 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 2024 | 0.020 |
Why?
|
| Mesothelioma | 3 | 1994 | 771 | 0.020 |
Why?
|
| Genes, ras | 1 | 2014 | 658 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 1238 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2016 | 2263 | 0.020 |
Why?
|
| Radioisotopes | 1 | 2013 | 495 | 0.020 |
Why?
|
| Mastectomy, Segmental | 2 | 2006 | 964 | 0.020 |
Why?
|
| Mice | 11 | 2015 | 81819 | 0.020 |
Why?
|
| Receptors, CCR3 | 2 | 2001 | 61 | 0.020 |
Why?
|
| Genotype | 2 | 2017 | 13024 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 1997 | 1272 | 0.020 |
Why?
|
| Esophagus | 1 | 2017 | 1037 | 0.020 |
Why?
|
| Body Composition | 1 | 2020 | 2439 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2018 | 4642 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2016 | 635 | 0.020 |
Why?
|
| Receptors, CCR4 | 2 | 2001 | 75 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 1996 | 4850 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 1599 | 0.020 |
Why?
|
| Carboplatin | 1 | 2013 | 789 | 0.020 |
Why?
|
| Fast Neutrons | 1 | 2010 | 18 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2015 | 1816 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2004 | 10729 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2014 | 893 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2505 | 0.020 |
Why?
|
| Apoptosis | 2 | 2009 | 9514 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2017 | 1180 | 0.020 |
Why?
|
| Necrosis | 1 | 2014 | 1617 | 0.020 |
Why?
|
| Fiber Optic Technology | 1 | 1991 | 284 | 0.020 |
Why?
|
| Photography | 1 | 2013 | 533 | 0.020 |
Why?
|
| Decision Trees | 1 | 1992 | 509 | 0.020 |
Why?
|
| Creatinine | 1 | 2015 | 1915 | 0.020 |
Why?
|
| Technology, Radiologic | 1 | 2010 | 158 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2018 | 2354 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 1993 | 990 | 0.020 |
Why?
|
| ras Proteins | 1 | 2014 | 1053 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 2210 | 0.020 |
Why?
|
| Bronchial Neoplasms | 1 | 1989 | 109 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2016 | 2666 | 0.020 |
Why?
|
| Reoperation | 2 | 2004 | 4294 | 0.020 |
Why?
|
| Benzamides | 1 | 2014 | 1377 | 0.020 |
Why?
|
| Mitral Valve Stenosis | 1 | 1990 | 343 | 0.020 |
Why?
|
| Random Allocation | 1 | 1993 | 2395 | 0.020 |
Why?
|
| Laser Therapy | 2 | 1993 | 1108 | 0.020 |
Why?
|
| Ovalbumin | 2 | 2000 | 674 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1992 | 791 | 0.020 |
Why?
|
| Cytarabine | 1 | 2010 | 698 | 0.020 |
Why?
|
| Hospital Records | 1 | 2008 | 93 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 1997 | 2176 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 950 | 0.020 |
Why?
|
| Pyrroles | 1 | 2014 | 1119 | 0.020 |
Why?
|
| Gadolinium | 1 | 2013 | 965 | 0.020 |
Why?
|
| Photochemistry | 1 | 1988 | 238 | 0.020 |
Why?
|
| Prescriptions | 1 | 2010 | 388 | 0.020 |
Why?
|
| Calcinosis | 1 | 1996 | 1479 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5719 | 0.020 |
Why?
|
| Kidney | 2 | 2017 | 7066 | 0.020 |
Why?
|
| Upper Extremity | 1 | 2012 | 682 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2020 | 22223 | 0.020 |
Why?
|
| Liver | 2 | 2017 | 7562 | 0.020 |
Why?
|
| Colon | 1 | 2015 | 1795 | 0.020 |
Why?
|
| Heart Neoplasms | 1 | 1990 | 375 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 1772 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 8923 | 0.020 |
Why?
|
| Rabbits | 1 | 1993 | 4734 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 1742 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 2233 | 0.020 |
Why?
|
| Telangiectasis | 1 | 2006 | 77 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1761 | 0.020 |
Why?
|
| Shoulder Pain | 1 | 2007 | 152 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 1728 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 4137 | 0.020 |
Why?
|
| Antigens, CD | 3 | 2001 | 4025 | 0.020 |
Why?
|
| Chylothorax | 1 | 2006 | 83 | 0.020 |
Why?
|
| Indoles | 1 | 2014 | 1839 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1992 | 1441 | 0.020 |
Why?
|
| Eosinophilia | 2 | 2001 | 556 | 0.020 |
Why?
|
| Cytokines | 4 | 2001 | 7421 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 1549 | 0.020 |
Why?
|
| Scapula | 1 | 2007 | 174 | 0.020 |
Why?
|
| Rats, Inbred F344 | 3 | 1992 | 822 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2016 | 3561 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1989 | 729 | 0.020 |
Why?
|
| Rats | 5 | 2001 | 23707 | 0.010 |
Why?
|
| Immunoglobulin E | 2 | 2001 | 1481 | 0.010 |
Why?
|
| Esthetics | 1 | 2006 | 326 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 5995 | 0.010 |
Why?
|
| Vagotomy | 1 | 1984 | 82 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2008 | 1144 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 2631 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2007 | 512 | 0.010 |
Why?
|
| Sinoatrial Node | 1 | 1984 | 99 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1994 | 2921 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 17075 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1988 | 2266 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2008 | 601 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3655 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1990 | 1140 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10603 | 0.010 |
Why?
|
| Gene Expression | 3 | 2001 | 7584 | 0.010 |
Why?
|
| Piperazines | 1 | 2014 | 2549 | 0.010 |
Why?
|
| Braces | 1 | 2004 | 139 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2003 | 119 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1989 | 909 | 0.010 |
Why?
|
| Signal Transduction | 3 | 2001 | 23601 | 0.010 |
Why?
|
| Cisplatin | 1 | 2009 | 1658 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1988 | 1229 | 0.010 |
Why?
|
| Mammaplasty | 1 | 2013 | 1264 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1999 | 7851 | 0.010 |
Why?
|
| Bradycardia | 1 | 1984 | 302 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1993 | 1471 | 0.010 |
Why?
|
| Rectum | 1 | 2007 | 896 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15652 | 0.010 |
Why?
|
| Anxiety | 1 | 2017 | 4671 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 2006 | 471 | 0.010 |
Why?
|
| Recurrence | 2 | 2007 | 8501 | 0.010 |
Why?
|
| Cricetulus | 1 | 1984 | 805 | 0.010 |
Why?
|
| Pelvis | 1 | 1986 | 738 | 0.010 |
Why?
|
| Allergens | 2 | 2000 | 1436 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2006 | 1831 | 0.010 |
Why?
|
| Medication Errors | 1 | 2008 | 786 | 0.010 |
Why?
|
| Risk Assessment | 3 | 2010 | 24282 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 4520 | 0.010 |
Why?
|
| Mitochondria | 1 | 2015 | 3673 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 5020 | 0.010 |
Why?
|
| Receptors, CCR8 | 1 | 2001 | 28 | 0.010 |
Why?
|
| Forecasting | 2 | 2001 | 2936 | 0.010 |
Why?
|
| Mental Health | 1 | 2016 | 3278 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 2001 | 150 | 0.010 |
Why?
|
| Cell Line | 3 | 2000 | 15543 | 0.010 |
Why?
|
| Health Personnel | 1 | 2015 | 3390 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 11022 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 75 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2007 | 1154 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2014 | 3595 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2008 | 2424 | 0.010 |
Why?
|
| Germinal Center | 1 | 2003 | 379 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2003 | 648 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1989 | 1935 | 0.010 |
Why?
|
| Parents | 1 | 2014 | 3592 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 2001 | 169 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2000 | 340 | 0.010 |
Why?
|
| Cricetinae | 1 | 1984 | 2411 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 2056 | 0.010 |
Why?
|
| Immune Sera | 1 | 2000 | 601 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 2878 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2001 | 961 | 0.010 |
Why?
|
| Stomatitis | 1 | 2002 | 270 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2018 | 26346 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2002 | 432 | 0.010 |
Why?
|
| Ovary | 1 | 1984 | 956 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2001 | 735 | 0.010 |
Why?
|
| Lymphocyte Activation | 2 | 2001 | 5501 | 0.010 |
Why?
|
| Enterotoxins | 1 | 2001 | 366 | 0.010 |
Why?
|
| Nausea | 1 | 2002 | 680 | 0.010 |
Why?
|
| Smoking | 1 | 2016 | 9081 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2006 | 1083 | 0.010 |
Why?
|
| Organizational Objectives | 1 | 2001 | 426 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2000 | 737 | 0.010 |
Why?
|
| Vomiting | 1 | 2002 | 647 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 8611 | 0.010 |
Why?
|
| Cell Movement | 2 | 2001 | 5194 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 1377 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2000 | 482 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 1999 | 243 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2000 | 455 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2003 | 1144 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 500 | 0.010 |
Why?
|
| Breast | 1 | 2006 | 1946 | 0.010 |
Why?
|
| COS Cells | 1 | 1999 | 1136 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 2000 | 9550 | 0.010 |
Why?
|
| Depression | 1 | 2017 | 8237 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2000 | 827 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2004 | 1162 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2001 | 813 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2001 | 696 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 15842 | 0.010 |
Why?
|
| Length of Stay | 1 | 2010 | 6485 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 4427 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2004 | 4860 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2000 | 1528 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2001 | 1146 | 0.010 |
Why?
|
| Crystallization | 1 | 1996 | 521 | 0.010 |
Why?
|
| Etoposide | 1 | 1996 | 636 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 4165 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2001 | 18973 | 0.010 |
Why?
|
| Interleukins | 1 | 1999 | 791 | 0.010 |
Why?
|
| Disease Models, Animal | 3 | 2001 | 18293 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6069 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 3475 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2003 | 11641 | 0.010 |
Why?
|
| Vincristine | 1 | 1996 | 1039 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2002 | 1088 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2001 | 9249 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 6274 | 0.010 |
Why?
|
| Brain | 2 | 1990 | 27171 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 366 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 1424 | 0.010 |
Why?
|
| Methohexital | 1 | 1992 | 17 | 0.010 |
Why?
|
| Thiopental | 1 | 1992 | 55 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 2599 | 0.010 |
Why?
|
| Medical Audit | 1 | 1993 | 452 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2001 | 22332 | 0.010 |
Why?
|
| Thoracotomy | 1 | 1994 | 369 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 5743 | 0.010 |
Why?
|
| Phenobarbital | 1 | 1992 | 192 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9338 | 0.010 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 1991 | 21 | 0.010 |
Why?
|
| Neutropenia | 1 | 1996 | 893 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1999 | 3160 | 0.010 |
Why?
|
| HIV Infections | 1 | 1997 | 17533 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 3737 | 0.010 |
Why?
|
| Monocytes | 1 | 2000 | 2595 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1992 | 914 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1996 | 779 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1999 | 2817 | 0.010 |
Why?
|
| Diazepam | 1 | 1990 | 215 | 0.000 |
Why?
|
| Contracture | 1 | 1991 | 234 | 0.000 |
Why?
|
| Dogs | 1 | 1994 | 3822 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 13400 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1996 | 1171 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 2000 | 4528 | 0.000 |
Why?
|
| Hypothermia | 1 | 1990 | 190 | 0.000 |
Why?
|
| Gastrectomy | 1 | 1993 | 694 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 17594 | 0.000 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 5508 | 0.000 |
Why?
|
| Receptors, GABA-A | 1 | 1990 | 624 | 0.000 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1991 | 730 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2001 | 14448 | 0.000 |
Why?
|
| Drug Resistance | 1 | 1991 | 1591 | 0.000 |
Why?
|
| Atropine | 1 | 1984 | 242 | 0.000 |
Why?
|
| Anesthesia, General | 1 | 1990 | 1172 | 0.000 |
Why?
|
| Vagus Nerve | 1 | 1984 | 460 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1992 | 5881 | 0.000 |
Why?
|
| Inflammation | 1 | 2001 | 10850 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1990 | 3672 | 0.000 |
Why?
|
| Skin | 1 | 1991 | 4489 | 0.000 |
Why?
|
| Myocardium | 1 | 1990 | 4760 | 0.000 |
Why?
|
| Heart Failure | 1 | 1996 | 11840 | 0.000 |
Why?
|